List of investigational antipsychotics

This is a list of investigational antipsychotics, or antipsychotics that are currently under development for clinical use but are not yet approved. Chemical/generic names are listed first, with developmental code names, synonyms, and brand names in parentheses.

Receptor modulators

Monoamine receptor modulators

• Brilaroxazine (RP-5063, RP-5000; oxaripiprazole) – atypical antipsychotic (D₂ receptor partial agonist, 5-HT_2A receptor antagonist, other actions)
• FKF-02SC (TGOF-02N) – atypical antipsychotic (D₂ and 5-HT_2A receptor antagonist, other actions)
• Masupirdine (SUVN-502) – 5-HT₆ receptor antagonist
• N-methyl amisulpride (LB-102) – D_2,3, 5-HT₇, receptor antagonists (methylated version of amisulpride)
• Ralmitaront (RG-7906, RO-6889450) – TAAR1 agonist
• Ulotaront (SEP-856, SEP-363856) – 5-HT_1A receptor and TAAR1 agonist
• Usmarapride (SUVN-D4010) – 5-HT₄ receptor partial agonist

Glutamate receptor modulators

• Pomaglumetad methionil (DB-103, LY-2140023, LY-2812223) – mGluR₂ and mGluR₃ agonist

Acetylcholine receptor modulators

• Emraclidine (CVL-231) – M₄ muscarinic acetylcholine receptor positive allosteric modulator.
• KarXT (xanomeline/trospium) – combined M₁ and M₄ muscarinic acetylcholine receptor agonist and peripherally-selective muscarinic acetylcholine receptor antagonist.
• ML-007 – M₁ and M₄ muscarinic acetylcholine receptor agonist.
• NBI-1117568 (HTL 0016878) – M₄ muscarinic acetylcholine receptor agonist.

Cannabinoid receptor modulators

• Cannabidiol (CBD; GW-42003, GWP-42003, GWP-42003-P, ECP-012A; Arvisol, Epidiolex) – cannabinoid receptor modulator, antioxidant, other actions

Other/mixed receptor modulators

• CVN766 – Orexin receptor type 1 antagonist
• Deudextromethorphan (d-DM; AVP-786, CTP-786) – σ₁ receptor agonist, serotonin–norepinephrine reuptake inhibitor, uncompetitive NMDA receptor antagonist, muscarinic acetylcholine receptor agonist, other actions
• Roluperidone (CYR-101, MIN-101, MT-210) – 5-HT_2A and σ₂ receptor antagonist
• TAK-041 (NBI 1065846) – GPR139 receptor agonist

Enzyme inhibitors

• Luvadaxistat (NBI 1065844, TAK-831) – D-amino acid oxidase inhibitor.
• MK-8189 – phosphodiesterase 10A inhibitor.
• Osoresnontrine (BI-409306, SUB-166499) – phosphodiesterase 9A inhibitor
• Sodium benzoate (SND-11, SND-12, SND-13, SND-14; Clozaben, NaBen) – D-amino acid oxidase inhibitor

Ion channel modulators

• Evenamide (NW-3509; NW-3509A) – Na_v1.3, Na_v1.7, and Na_v1.8 voltage-gated sodium channel blocker

Others

• TS-134 (TS-1341) – undefined mechanism of action

See also

• List of investigational drugs

External links

• AdisInsight – Springer
• 2016 Medicines in Development for Mental Health – PhRMA